Security
Definium Therapeutics, Inc. Common Shares · DFTX
DFTXNASDAQCommon stockCurrentCIK 1813814Updated Nov 17, 2026
DFTX price & chart
Loading TradingView…
NASDAQ:DFTX on TradingView ↗About the company
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.
In the news
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions ↗
Seeking Alpha
Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated ↗
DEA looks to increase legal psychedelics production for medical research ↗
Definium plans DT120 NDA filing in H1 2027 as cash runway extends into 2030 ↗
SEC disclosures
Definium Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G - filed by Janus Henderson Group Ltd. regarding Definium Therapeutics, Inc.
SCHEDULE 13G - filed by Capital World Investors regarding Definium Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by FMR LLC regarding Definium Therapeutics, Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 236,916,000Source | 319,769,000Source | 1,112,899,000Source | 265,091,000Source | 268,145,000Source | 401,293,000Source | 275,323,000Source | 275,533,000Source | 440,100,000Source | 302,151,000Source | 124,541,000Source | 169,993,000Source |
| GoodwillUSD | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 19,959,000Source | 295,284,000Source | 655,267,000Source | 33,392,000Source | 243,132,000Source | 262,518,000Source | 82,854,000Source | 252,332,000Source | 257,837,000Source | 273,741,000Source | 99,704,000Source | 142,142,000Source |
| Assets, CurrentUSD | 215,848,000Source | 299,358,000Source | 1,092,101,000Source | 189,136,000Source | 247,693,000Source | 380,563,000Source | 221,700,000Source | 255,471,000Source | 419,320,000Source | 281,620,000Source | 103,872,000Source | 146,055,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,778,000Source | 4,074,000Source | 8,222,000Source | 6,143,000Source | 4,561,000Source | 7,141,000Source | 9,259,000Source | 3,139,000Source | 7,727,000Source | 7,879,000Source | 4,168,000Source | 3,913,000Source |
| Other Assets, NoncurrentUSD | 1,150,000Source | 493,000Source | 880,000Source | 1,174,000Source | 534,000Source | 812,000Source | 606,000Source | 144,000Source | 862,000Source | 613,000Source | 224,000Source | 331,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 106,320,000Source | 57,576,000Source | 194,220,000Source | 79,691,000Source | 66,098,000Source | 122,444,000Source | 52,517,000Source | 79,474,000Source | 107,773,000Source | 60,703,000Source | 46,407,000Source | 19,076,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 0Source | — | — | 0Source | — | — | — | — | 0Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -532,236,000Source | -364,138,000Source | -818,756,000Source | -464,971,000Source | -350,454,000Source | -659,770,000Source | -422,227,000Source | -344,600,000Source | -582,672,000Source | -398,879,000Source | -290,200,000Source | -194,468,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,001,000Source | 821,000Source | 417,000Source | 807,000Source | 833,000Source | 824,000Source | 802,000Source | 836,000Source | 1,085,000Source | 819,000Source | 343,000Source | 627,000Source |
| Stockholders' Equity Attributable to ParentUSD | 130,596,000Source | 262,193,000Source | 918,679,000Source | 185,400,000Source | 202,047,000Source | 278,849,000Source | 222,806,000Source | 196,059,000Source | 332,327,000Source | 241,448,000Source | 78,134,000Source | 150,917,000Source |
| Additional Paid in Capital, Common StockUSD | 661,831,000Source | 625,510,000Source | 1,737,018,000Source | 649,564,000Source | 551,668,000Source | 937,795,000Source | 644,231,000Source | 539,823,000Source | 913,914,000Source | 639,508,000Source | 367,991,000Source | 344,758,000Source |
| Liabilities and EquityUSD | 236,916,000Source | 319,769,000Source | 1,112,899,000Source | 265,091,000Source | 268,145,000Source | 401,293,000Source | 275,323,000Source | 275,533,000Source | 440,100,000Source | 302,151,000Source | 124,541,000Source | 169,993,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 65,416,000Source | 33,265,000Source | 157,204,000Source | 37,957,000Source | 41,847,000Source | 81,112,000Source | 30,481,000Source | 65,269,000Source | 66,698,000Source | 38,849,000Source | 32,246,000Source | 17,892,000Source |
| Accounts Payable, CurrentUSD | 8,113,000Source | 2,149,000Source | 6,965,000Source | 4,216,000Source | 2,936,000Source | 7,127,000Source | 2,268,000Source | 7,595,000Source | 5,347,000Source | 2,010,000Source | 4,136,000Source | 2,111,000Source |
| Other Liabilities, NoncurrentUSD | 519,000Source | — | 549,000Source | 543,000Source | — | 559,000Source | — | 15,000Source | 496,000Source | — | 32,000Source | 1,184,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 19,028,000Source | 8,796,000Source | 37,222,000Source | 14,797,000Source | 8,231,000Source | 24,514,000Source | 11,497,000Source | 9,974,000Source | 20,446,000Source | 12,829,000Source | 11,634,000Source | 5,877,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 40,385,000Source | 24,311,000Source | 36,467,000Source | 41,191,000Source | 24,251,000Source | 40,773,000Source | 22,036,000Source | 14,190,000Source | 40,579,000Source | 21,854,000Source | 14,129,000Source | — |
| Short-term InvestmentsUSD | 189,111,000Source | — | 428,612,000Source | 149,601,000Source | — | 110,904,000Source | 129,587,000Source | — | 153,756,000Source | — | — | — |
| Operating Lease, Right-of-Use Asset | — | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -77,098,000Source | -23,348,000Source | -183,793,000Source | -108,679,000Source | -95,732,000Source | -56,796,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,780,000Source | 258,000Source | 3,337,000Source | -2,126,000Source | 2,025,000Source | -2,056,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -42,631,000Source | -29,419,000Source | -131,560,000Source | -79,129,000Source | -64,365,000Source | -50,139,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 42,000,000Source | -162,458,000Source | -151,606,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | 0Source | 0Source | 54,000Source | — | 407,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,309,000Source | 1,002,000Source | 267,269,000Source | 253,196,000Source | 21,848,000Source | 59,051,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 4,681,000Source | -190,887,000Source | -15,904,000Source | 174,037,000Source | -42,438,000Source | 8,603,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,051,000Source | 602,000Source | 5,338,000Source | 2,224,000Source | 534,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,816,000Source | 3,841,000Source | 9,639,000Source | 5,253,000Source | 7,132,000Source | 3,426,000Source | 20,096,000Source | 16,913,000Source | 15,494,000Source | 13,707,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | 725,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 527,000Source | 3,162,000Source | 3,180,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -39,000Source | -32,000Source | -32,000Source | -49,000Source | -44,000Source | -19,000Source | -131,000Source | -638,000Source | 157,000Source | 195,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | 0Source | 0Source | -506,000Source | 363,000Source | 148,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | 2,541,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 14,691,000Source | 7,604,000Source | 26,412,000Source | 11,094,000Source | 17,736,000Source | 8,802,000Source | 48,644,000Source | 38,619,000Source | 41,742,000Source | 30,162,000Source |
| GoodwillUSD | — | — | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source | 19,918,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -67,265,000Source | -13,684,000Source | -158,986,000Source | -42,744,000Source | -77,098,000Source | -23,348,000Source | -183,793,000Source | -108,679,000Source | -95,732,000Source | -56,796,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -67,265,000Source | -13,684,000Source | -158,986,000Source | -42,744,000Source | -77,098,000Source | -23,348,000Source | -183,793,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 45,669,000Source | 24,792,000Source | 75,077,000Source | 40,903,000Source | 59,220,000Source | 32,159,000Source | 166,309,000Source | 103,916,000Source | 93,866,000Source | 66,331,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,596,000Source | 11,108,000Source | -83,909,000Source | -1,841,000Source | -17,878,000Source | 8,811,000Source | -17,484,000Source | -4,763,000Source | -1,866,000Source | 9,535,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | 0Source | 447,000Source | 128,000Source | 844,000Source | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 0Source | 162,458,000Source | 268,356,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 984,000Source | 7,529,000Source | 42,297,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 42,000,000Source | 0Source | 116,750,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,196,000Source | 237,000Source | 625,000Source | 716,000Source | 49,000Source | 206,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 196,000Source | — | -406,000Source | 36,000Source | -262,000Source | 10,000Source | 330,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -45,669,000Source | -24,792,000Source | -75,077,000Source | -40,903,000Source | -59,220,000Source | -32,159,000Source | -166,309,000Source | -103,916,000Source | -93,866,000Source | -66,331,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,596,000Source | 11,108,000Source | -83,909,000Source | -1,841,000Source | -17,878,000Source | 8,811,000Source | -17,484,000Source | -4,763,000Source | -1,866,000Source | 9,535,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -183,793,000Source | -108,679,000Source | -95,732,000Source | -56,796,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -67,265,000Source | -13,684,000Source | -158,986,000Source | -42,744,000Source | -77,098,000Source | -23,348,000Source | -183,793,000Source | -108,679,000Source | -95,732,000Source | -56,796,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.78Source | -0.18Source | -1.44Source | -0.5Source | -0.71Source | -0.27Source | -2.06Source | -1.54Source | -2.44Source | -1.84Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.78Source | -0.27Source | -1.44Source | -0.5Source | -0.71Source | -0.35Source | -2.06Source | -1.54Source | -2.44Source | -1.84Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 85,885,516Source | 77,909,441Source | 110,684,720Source | 85,347,677Source | 108,790,941Source | 85,067,855Source | 89,327,608Source | 70,461,067Source | 39,157,420Source | 30,857,463Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 85,885,516Source | 80,238,688Source | 110,684,720Source | 85,347,677Source | 108,790,941Source | 87,091,461Source | 89,327,608Source | 70,461,067Source | 39,157,420Source | 30,857,463Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 527,000Source | 3,162,000Source | 3,180,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -39,000Source | -32,000Source | -32,000Source | -49,000Source | -44,000Source | -19,000Source | -131,000Source | -638,000Source | 157,000Source | 195,000Source |
| General and Administrative ExpenseUSD | — | — | 14,691,000Source | 7,604,000Source | 26,412,000Source | 11,094,000Source | 17,736,000Source | 8,802,000Source | 48,644,000Source | 38,619,000Source | 41,742,000Source | 30,162,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -159,844,000Source | -123,631,000Source | -89,536,000Source | -61,763,000Source |
| Interest ExpenseUSD | — | — | 1,274,000Source | 727,000Source | 1,233,000Source | 2,338,000Source | 1,245,000Source | 602,000Source | 5,482,000Source | 2,283,000Source | — | — |
| Interest Expense, DebtUSD | — | — | 1,300,000Source | 700,000Source | — | 2,300,000Source | 1,200,000Source | 600,000Source | 5,500,000Source | 2,300,000Source | 700,000Source | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 4,664,000Source | 1,495,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -67,265,000Source | -13,684,000Source | -158,986,000Source | -42,744,000Source | -77,098,000Source | -23,348,000Source | -183,793,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 45,669,000Source | 24,792,000Source | 75,077,000Source | 40,903,000Source | 59,220,000Source | 32,159,000Source | 166,309,000Source | 103,916,000Source | 93,866,000Source | 66,331,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | -51,000Source | 2,000Source |
| Research and Development ExpenseUSD | — | — | 30,978,000Source | 17,188,000Source | 48,665,000Source | 29,809,000Source | 41,484,000Source | 23,357,000Source | 117,665,000Source | 65,297,000Source | 52,124,000Source | 36,169,000Source |
Filing attachments
dftx-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder (MDD) On track for DT120 ODT NDA filing in first half of 2027 DT402 demonstrated positive initial results in a Phase 2a trial in adults with autism spectrum disorder (ASD); clinical stud…
Read attachment ↗tm2625365d1_ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 tm2625365d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODT Participants receiving DT120 ODT 100 µg achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-…
Read attachment ↗tm2625365d1_ex99-2.htm · 8-K · 2026-09-14
EX-99.2 3 tm2625365d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Phase 3 Panorama Study Topline Data Readout This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an off er to purchase, securities of Definium and under no circumstances is it to be construed as a prospectus or advertisement or public offer…
Read attachment ↗dftx-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 dftx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results Second FDA Breakthrough Therapy designation for DT120 reinforces its potential across MDD and generalized anxiety disorder (GAD), two disorders with significant unmet need NEW YORK -- Definium Therapeutics, Inc. (“Definium” or the “Company”), a l…
Read attachment ↗tm2622948d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622948d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder Study met primary and all key secondary efficacy endpoints Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81) DT120 ODT was general…
Read attachment ↗tm2622948d1_ex99-2.htm · 8-K · 2026-08-12
EX-99.2 3 tm2622948d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Phase 3 Voyage Study Topline Data Readout This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an off er to purchase, securities of Definium and under no circumstances is it to be construed as a prospectus or advertisement or public offerin…
Read attachment ↗